Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

The "Quad"

March/April 2012

Brand name: Not yet established

Generic name: elvitegravir/cobicistat/emtricitabine/tenofovir, or EVG/COBI/FTC/TDF

Class: Boosted integrase inhibitor and NRTI -- single-tablet regimen (STR)

Manufacturer: Gilead Sciences, www.gilead.com, (800) GILEAD-5 (445-3235)

AWP: TBD; drug not yet approved at press time.

Standard Dose: One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/300 mg tenofovir ) once daily has been selected in the Phase 3 studies. Take missed dose as soon as possible, unless it is closer in time to your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney problems.

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Visit Positively Aware's website to find out more about the publication.
 
See Also
The 16th Annual HIV Drug Guide
More Research on Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement